Latest news

• Roche’s Soliris rival satralizumab scores in phase 3 study

  This group reflects a real-world population of adolescents and adults with NMOSD who tend to experience a more severe disease course. ... It was approved to treated NMOSD in adult patients who are AQP4 antibody positive.

• US, EU regulators start review of Roche’s Soliris rival satralizumab

  Meanwhile, another emerging rival in the NMOSD category is  Viela Bio, whose inebilizumab was filed for approval with the FDA earlier this year. ... Roche says NMOSD affects over 10, 000 people in Europe, 15, 000 people in the US and 'up to hundreds of

• Alexion eyes Soliris combo with $930m deal to buy Achillion

  in 2018, thanks to new indications such as generalised myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) that have broadened its reach.

• Roche presents new data in NMOSD, could challenge Alexion's Soliris

  NMOSD disproportionately affects young women in the prime of their lives, with the average age of onset just 39 years. ... It became the first FDA-approved treatment for NMOSD at that time, but competitors, including Roche, are hot on its heels.

• Medimmune-born Viela files $150m IPO, eyes first product launch

  It is estimated there are around 16, 000 people with NMOSD in the US. ... Meanwhile, Japan’s Chugai also has positive phase 3 data with its NMOSD candidate satralizumab, an interleukin-6 inhibitor partnered with Roche.